A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
- 1 December 2013
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 11 (4) , 477-483
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialThe Lancet Oncology, 2012
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75Journal of Clinical Oncology, 2011
- Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activityAnnals of Oncology, 2011
- Phase II Study of Sunitinib in Patients With Metastatic Urothelial CancerJournal of Clinical Oncology, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Phase 2 trial of sorafenib in patients with advanced urothelial cancerCancer, 2009
- Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMolecular Cancer Therapeutics, 2007
- VEGF receptor expression and signaling in human bladder tumorsOncogene, 2003
- Angiogenesis in Bladder Cancer: Relationship Between Microvessel Density and Tumor PrognosisJNCI: Journal of the National Cancer Institute, 1995
- Confidence Intervals for a Binomial Parameter Based on Multistage TestsBiometrics, 1987